Cost-effectiveness analysis of emicizumab prophylaxis in patients with haemophilia A in India.
Tulika SethM Joseph JohnPrantar ChakrabartiChandrakala ShanmukhaiahShailendra Prasad VermaNita RadhakrishnanTuphan Kanti DolaiPublished in: Haemophilia : the official journal of the World Federation of Hemophilia (2023)
Emicizumab prophylaxis is cost-effective compared to HDP and provides value for money compared to ODT, IDP, and LDP for severe non-inhibitor PwHA in India. Its long-term humanistic, clinical and economic benefits outweigh alternative options, making it a valuable choice in resource-constrained settings.
Keyphrases